Invention Grant
- Patent Title: CDK2 inhibitors
-
Application No.: US17850453Application Date: 2022-06-27
-
Publication No.: US11932648B2Publication Date: 2024-03-19
- Inventor: Douglas Wilson , Neil Bifulco, Jr. , Natasja Brooijmans , Joseph L. Kim , Emanuele Perola , Philip D. Ramsden , Richard Vargas , Steven Mark Wenglowsky
- Applicant: BLUEPRINT MEDICINES CORPORATION
- Applicant Address: US MA Cambridge
- Assignee: BLUEPRINT MEDICINES CORPORATION
- Current Assignee: BLUEPRINT MEDICINES CORPORATION
- Current Assignee Address: US MA Cambridge
- Agency: Goodwin Procter LLP
- Main IPC: C07D487/04
- IPC: C07D487/04 ; A61K31/4985 ; A61K31/519 ; A61K45/06 ; A61P35/00 ; C07D519/00
Abstract:
The present disclosure provides a compound represented by structural Formula (I):
or a pharmaceutically acceptable salt thereof useful for treating a cancer.
or a pharmaceutically acceptable salt thereof useful for treating a cancer.
Public/Granted literature
- US20230159535A1 CDK2 INHIBITORS Public/Granted day:2023-05-25
Information query
